Every material Form 8-K Ainos, Inc. has filed with the SEC since August 03, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Ainos's board approved Second Amended and Restated Bylaws on October 14, 2026, effective immediately, dividing directors into three classes with staggered three-year terms. The board also amended its Corporate Governance Policies to reflect the new structure, so shareholders will elect only one class of directors at each annual meeting.
Board unanimously approved the restated bylaws on October 14, 2026, effective immediately
Class I (term expires at 2026 annual meeting): Ting-Chuan Lee, Chun-Jung Tsai, Chung-Yi Tsai
Class II (term expires at 2027 annual meeting): Yao-Chung Chiang, Pao-Sheng Wei; Class III (term expires at 2028 annual meeting): Chun-Hsien Tsai, Wen-Han Chang
Amended Corporate Governance Policies filed as Exhibit 99.1; restated bylaws filed as Exhibit 3.1
Ainos entered into a Global Exclusive License Agreement with BioPhoenix Co., Ltd. dated September 24, 2026, covering its VELDONA low-dose oral interferon alpha platform for Sjögren's Disease and Thrombocytopenia. BioPhoenix will pay a $600,000 upfront fee and receives a 25% share of Ainos' net sublicensing revenue for these indications, with BioPhoenix funding the clinical and regulatory work. Ainos also agreed not to compete with the licensed indications during the term and for 10 years afterward.
Upfront license fee of $600,000, due after BioPhoenix receives the complete data package and written confirmation that technology transfer is complete
Total license fees would be approximately $10.0 million if BioPhoenix licenses all additional VELDONA indications, including the first sublicense fee
Ainos receives 25% of BioPhoenix's net sublicensing revenue for the Licensed Indications
Agreement runs until the later of patent expiration or 20 years after September 24, 2026, and Ainos may not compete for 10 years after it ends
Ainos reported second-quarter 2026 results for the period ended June 30, 2026. Revenue fell from $4,663 a year earlier to $152, and the net loss widened to $4,594,731 from $4,084,990, although the per-share loss narrowed to $0.62 from $0.99 as the share count rose. Shareholders face a sharp revenue decline, $11,000,000 in convertible notes now classified as current liabilities, and stockholders' equity that fell to $3,283,985 from $7,562,582.
Q2 2026 revenue was $152, versus $4,663 in Q2 2025; six-month revenue was $313, versus $110,870.
Q2 2026 net loss was $4,594,731, versus $4,084,990 a year earlier; basic and diluted loss per share was $0.62, versus $0.99.
Cash and cash equivalents rose to $1,422,912 at June 30, 2026, from $417,353 at December 31, 2025.
Convertible notes payable of $11,000,000 and a loan payable of $2,812,940 were current liabilities at June 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Ainos, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →